{"entity":{"id":"idea-nl-glp1-adjuvant-hr-breast","kind":"idea","name":"GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer","aka":[],"tldr":"Coaching-based weight loss did not clearly cut breast cancer recurrence in BWEL, perhaps because the weight loss was too small. Drugs that produce three times as much weight loss could settle whether weight itself matters.","summary":"BWEL achieved modest weight loss with no clear iDFS effect. Bariatric surgery cohorts, with 25-30% weight loss, show large reductions in hormone-related cancers. GLP-1 receptor agonists sit between the two and are already widely used by breast cancer survivors off-trial; a randomised trial would answer the biological question BWEL could not and define safety alongside endocrine therapy (lean mass loss, bone density, gastrointestinal effects with CDK4/6 inhibitors).","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Survivorship and late effects are neglected): NCI Office of Cancer Survivorship statistics","url":"https://cancercontrol.cancer.gov/ocs/statistics"}],"tags":[],"related":["idea-prev-glp1-cancer-prevention-rct"],"cancers":["breast-hr-positive"],"sections":["nutrition-lifestyle","hormonal"],"technologies":["glp1-agonists-cancer-risk","dietitian-led-weight-loss-breast","endocrine-therapy","resistance-training-cachexia"],"targets":[],"drugs":["letrozole","abemaciclib"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":["obesity-related-cancers","energy-balance","body-composition"],"trials":["bwel"],"people":[],"bottlenecks":["b-survivorship","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"In women with stage II-III HR-positive breast cancer and BMI at least 30 on adjuvant endocrine therapy, two years of semaglutide or tirzepatide with resistance exercise improves invasive disease-free survival compared with lifestyle counselling alone, with the effect mediated by weight loss and reduced insulin and oestradiol.","rationale":"Obesity is associated with about 30% higher breast cancer mortality and with reduced aromatase inhibitor efficacy; GLP-1 receptor agonists produce sustained 15-20% weight loss; observational data suggest lower obesity-related cancer incidence. The exercise component protects lean mass, which rapid weight loss otherwise depletes.","test":"Phase 3 placebo-controlled trial (about 3,000 women) with iDFS primary endpoint, body composition by DXA, bone density and patient-reported outcomes; pre-specified mediation analysis by percentage weight loss. An industry-academic partnership is realistic given the commercial value of a cancer label.","maturity":"speculative","actor":"industry","cost":"large","horizonYears":8},"route":"/ideas/idea-nl-glp1-adjuvant-hr-breast/","neighbours":{"idea":[{"id":"idea-prev-glp1-cancer-prevention-rct","kind":"idea","name":"A trial of GLP-1 weight-loss drugs with cancer as the primary outcome","route":"/ideas/idea-prev-glp1-cancer-prevention-rct/"}],"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/"},{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"}],"technology":[{"id":"dietitian-led-weight-loss-breast","kind":"technology","name":"Dietitian-led weight-loss programmes in HR-positive breast cancer","route":"/technologies/dietitian-led-weight-loss-breast/"},{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"},{"id":"glp1-agonists-cancer-risk","kind":"technology","name":"GLP-1 receptor agonists and obesity-related cancer risk","route":"/technologies/glp1-agonists-cancer-risk/"},{"id":"resistance-training-cachexia","kind":"technology","name":"Resistance training and protein for cachexia and sarcopenia","route":"/technologies/resistance-training-cachexia/"}],"drug":[{"id":"abemaciclib","kind":"drug","name":"Abemaciclib","route":"/drugs/abemaciclib/"},{"id":"letrozole","kind":"drug","name":"Letrozole (and other aromatase inhibitors)","route":"/drugs/letrozole/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}],"term":[{"id":"body-composition","kind":"term","name":"Body composition (lean mass, fat mass, visceral fat)","route":"/terms/body-composition/"},{"id":"energy-balance","kind":"term","name":"Energy balance","route":"/terms/energy-balance/"},{"id":"obesity-related-cancers","kind":"term","name":"Obesity-related cancers (IARC list of 13)","route":"/terms/obesity-related-cancers/"}],"trial":[{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}